{"id":7795,"date":"2026-02-24T06:08:26","date_gmt":"2026-02-24T06:08:26","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/cjc-1295-ipamorelin\/"},"modified":"2026-04-09T14:26:00","modified_gmt":"2026-04-09T21:26:00","slug":"cjc-1295-ipamorelin","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/cjc-1295-ipamorelin\/","title":{"rendered":"CJC-1295 + Ipamorelin \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to CJC-1295 + Ipamorelin product page<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on these compounds \u2014 for educational purposes only<\/p>\n

\nGHRH and GHS Receptor Synergistic Signaling<\/summary>\n
\n

The combination of GHRH analogs with growth hormone secretagogues (GHS) has been investigated for synergistic effects on somatotroph cells. GHRH activates the GHRH receptor (a class B GPCR) through cAMP\/PKA signaling, while GHS peptides like ipamorelin activate the GHS-R1a receptor through phospholipase C\/IP3\/calcium pathways. Co-stimulation of both receptor systems on the same pituitary cell produces GH release that exceeds the sum of individual stimulations, as characterized in perfused rat pituitary models.<\/p>\n

Bowers CY et al. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology.<\/em> 1984. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nIpamorelin Selectivity Profile<\/summary>\n
\n

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH\u2082) is a pentapeptide GH secretagogue characterized by high selectivity for GH release relative to other pituitary hormones. In swine pituitary cell culture models, ipamorelin stimulated GH release with an EC\u2085\u2080 of approximately 1.3 nM without significant effects on ACTH, cortisol, prolactin, or FSH\/LH release at effective concentrations. This selectivity profile distinguishes it from earlier GHS compounds like GHRP-6 and hexarelin, which show broader hormonal stimulation.<\/p>\n

Raun K et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol.<\/em> 1998. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nCJC-1295 (Mod GRF 1-29) Structure and Pharmacokinetics<\/summary>\n
\n

CJC-1295 without DAC (also known as Modified GRF 1-29) is a tetra-substituted analog of GHRH(1-29) with modifications at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). These substitutions confer resistance to DPP-IV and other proteolytic enzymes, extending the biological half-life from the approximately 7-minute native GHRH half-life to roughly 30 minutes. The peptide retains full agonist activity at the GHRH receptor with equivalent binding affinity to native GHRH(1-29).<\/p>\n

Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab.<\/em> 2006. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to CJC-1295 + Ipamorelin product page Research Library Published research on these compounds \u2014 for educational purposes only GHRH and GHS Receptor Synergistic Signaling The combination of GHRH analogs with growth hormone secretagogues (GHS) has been investigated for synergistic effects on somatotroph cells. GHRH activates the GHRH receptor (a class B GPCR) through […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7795","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7795"}],"version-history":[{"count":1,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7795\/revisions"}],"predecessor-version":[{"id":8626,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7795\/revisions\/8626"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}